aTyr Pharma (STU:471A) E10: €-9.23 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:471A aTyr Pharma Inc STU:471A
27 GF Score
Price €0.42
GF Value €0.38
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is aTyr Pharma E10?

aTyr Pharma STU:471A -4.59% 27 E10 is €-9.23 as of Mar. 2026. GuruFocus rates STU:471A with a GF Score™ of 27/100 and a GF Value™ of €0.38 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

aTyr Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.095. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-9.23 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-27), aTyr Pharma's current stock price is €0.416. aTyr Pharma's E10 for the quarter that ended in Mar. 2026 was €-9.23. aTyr Pharma's Shiller PE Ratio of today is .


aTyr Pharma  (STU:471A) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


aTyr Pharma E10 Related Terms


aTyr Pharma E10 Historical Data

* Premium members only.

The historical data trend for aTyr Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

aTyr Pharma E10 Chart

aTyr Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -18.02 -15.39 -9.42

aTyr Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.96 -12.10 -13.88 -9.42 -9.23

STU:471A vs IBO, BYSI, MCRB: E10 Comparison

For the Biotechnology subindustry, aTyr Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


aTyr Pharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's Shiller PE Ratio falls into.


STU:471A
27GF Score
aTyr Pharma Inc STU:471A
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

aTyr Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, aTyr Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.095/330.2130*330.2130
=-0.095

Current CPI (Mar. 2026) = 330.2130.

aTyr Pharma Quarterly Data

per share eps CPI Adj_EPS
201606 -8.099 241.018 -11.096
201609 -7.235 241.428 -9.896
201612 -7.034 241.432 -9.621
201703 -7.330 243.801 -9.928
201706 -6.355 244.955 -8.567
201709 -5.051 246.819 -6.758
201712 -4.614 246.524 -6.180
201803 -4.087 249.554 -5.408
201806 -4.177 251.989 -5.474
201809 -2.854 252.439 -3.733
201812 -2.584 251.233 -3.396
201903 -2.248 254.202 -2.920
201906 -1.593 256.143 -2.054
201909 -1.335 256.759 -1.717
201912 -1.386 256.974 -1.781
202003 0.226 258.115 0.289
202006 -0.613 257.797 -0.785
202009 -0.577 260.280 -0.732
202012 -0.386 260.474 -0.489
202103 -0.428 264.877 -0.534
202106 -0.531 271.696 -0.645
202109 -0.357 274.310 -0.430
202112 -0.274 278.802 -0.325
202203 -0.400 287.504 -0.459
202206 -0.416 296.311 -0.464
202209 -0.465 296.808 -0.517
202212 -0.245 296.797 -0.273
202303 -0.271 301.836 -0.296
202306 -0.203 305.109 -0.220
202309 -0.187 307.789 -0.201
202312 -0.229 306.746 -0.247
202403 -0.212 312.332 -0.224
202406 -0.214 314.175 -0.225
202409 -0.207 315.301 -0.217
202412 -0.172 315.605 -0.180
202503 -0.157 319.799 -0.162
202506 -0.191 322.561 -0.196
202509 -0.222 324.800 -0.226
202512 -0.120 324.054 -0.122
202603 -0.095 330.213 -0.095

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-9.23 mean?
aTyr Pharma (STU:471A) has a E10 of €-9.23 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on aTyr Pharma and its competitors.
Is aTyr Pharma's E10 too high?
aTyr Pharma's current E10 is €-9.23. Overall, aTyr Pharma has a GF Score™ of 27/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's E10 compare to IBO and BYSI?
aTyr Pharma's E10 of €-9.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on aTyr Pharma and its competitors. aTyr Pharma's current E10 is €-9.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (STU:471A) is currently considered Fairly Valued. The stock's GF Value™ is €0.38, compared to a current price of €0.42 — trading 9.5% above its estimated fair value. The current E10 is €-9.23. aTyr Pharma's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For aTyr Pharma (STU:471A), the current E10 is €-9.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is aTyr Pharma (STU:471A) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued. The current stock price of €0.42 is trading 9.5% above its estimated GF Value™ of €0.38. GuruFocus considers aTyr Pharma to be Fairly Valued.

Key valuation signals for STU:471A:

  • E10: €-9.23
  • GF Value™: €0.38 vs. price of €0.42 (9.5% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the STU:471A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


aTyr Pharma Business Description

Other Exchanges ATYR:USA
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
27GF Score

Get the complete analysis for STU:471A

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.42
Price
€0.38
GF Value